Active Pharmaceutical Ingredients (API) Global Market - Forecast to 2022

Publishing Date : May, 2016
Report Code : HCPH 0100
Price:
Single license $4,500
Site license $6,300
Global license $9,000


Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having direct effect on diagnosis or treatment of disease. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from natural source. API market is mainly driven by the factors such as patent expiration of blockbuster drugs, increased generic medicine sales and high uptake of biologics. High Potential Active Pharmaceutical Ingredients (HPAPI) is booming in API market globally as these compounds are very effective in treatment of diseases such as cancer, respiratory disorders and hormonal imbalances and HPAPI growth is mainly driven by its therapeutic applications in oncology.


As estimated by IQ4I Research the global Active Pharmaceutical Ingredient market is valued to be $XX billion in 2015 and poised to grow at a CAGR of X% to reach $258.5 billion by 2022. API market is segmented by synthesis including synthetic chemicals, HPAPI and biotech API. In synthesis API market, synthetic chemicals holds major share of XX% and biotech API is fastest growing segment at a CAGR of XX%. Biotech API is further segmented into monoclonal antibodies, recombinant proteins, vaccines and others. Recombinant proteins accounted for highest share of XX% in 2015 and monoclonal antibodies is fastest growing segment at X% CAGR. By customer base it is segmented into synthetic chemicals, biotech API and HPAPI, synthetic chemicals are further segmented as branded/innovative and generic/non branded. Biotech API is segmented as biologics/innovative and biosimilars/non branded. By business type, captive market holds major share with XX% and merchant market is fastest growing segment with a CAGR of XX% from 2015 to 2022. By therapeutic applications, it is segmented into anti-infectives, oncology, cardiovascular and hematopoietic system, central nervous system, respiratory system, gastrointestinal, hormonal related disorders, metabolic disorders, genito-urinary disorders, musculo-skeletal disorders and others. In application segment, anti-infectives holds major share of XX% and oncology is fastest growing segment at a CAGR of X%. Geography segment is divided into North America, Europe, Asia-Pacific, rest of the world (ROW) where North America holds largest share of XX% and Asia-Pacific is fastest growing region with a CAGR of X% from 2015 to 2022.

In addition, capacity utilization rate and number of manufacturing units by landscape are identified. North America holds largest share in API market due to patent expiry of drugs, aging population, rising demand for anti-cancer drugs, established R&D infrastructure for novel drug development and increased generic medicine sales. Asia-Pacific (APAC) holds second major share and is fastest growing market followed by Europe and Rest of the world. Emerging countries such as China, India and Italy are major contributors due to low labor and manufacturing costs, government emphasis on healthcare reforms.

Factors such as government initiations for biomedical research, rising cancer prevalence across the world, increasing regional penetration, rising population with life style and aged related disorders, increasing mergers and acquisitions and expansion of local manufacturers are providing growth opportunities for API market whereas stringent regulatory affairs, financial crisis, less investors for API manufacturing ingredients and high market fragmentation are hampering API market growth.

The Active Pharmaceutical Ingredient global market is a highly competitive market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the key players contributing at global level for Active Pharmaceutical Ingredient (API) market growth are Albemarle Corporation (U.S.), Aurobindo Pharma Limited (India), Boehringer Ingelheim GmbH (Germany), Fresenius Kabi (Germany), Lupin Pharmaceuticals Inc (India), Teva Pharmaceutical Industries LTD (Israel), Lonza Group (Switzerland), Novartis AG (Switzerland), Sun Pharmaceutical Industries LTD (India) and Dr. Reddy’s Laboratories (India).

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET CRACK DOWN & DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     KEY DATA POINTS FROM SECONDARY RESOURCES
      • 2.5.5     PRIMARY SOURCES
      • 2.5.6     KEY DATA POINT FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     PATENT EXPIRATION OF MAJOR DRUGS ENHANCED GENERICS SALES
        • 3.3.1.2     GOVERNMENT INITIATION ON BIOMEDICAL RESEARCH
        • 3.3.1.3     INCREASING SCOPE OF HPAPI MARKET
        • 3.3.1.4     HIGH UPTAKE OF BIOLOGICS ACROSS DIVERSE THERAPEUTIC AREAS
        • 3.3.1.5     INCREASING REGIONAL PENETRATION AND AGED POPULATION
        • 3.3.1.6     INCREASING MERGERS AND ACQUISITIONS
        • 3.3.1.7     EXPANSION OF LOCAL API MANUFACTURERS
        • 3.3.1.8     GLOBAL API OUTSOURCING
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     DELAY IN APPROVAL OF NEW DRUGS
        • 3.3.2.2     LOW INVESTMENT IN API MARKET DUE TO ECONOMIC DOWNTURN
        • 3.3.2.3     HIGH PRODUCTION COST FOR MANUFACTURING APIS
        • 3.3.2.4     FIERCE COMPETITION BETWEEN API PLAYERS
        • 3.3.2.5     STRINGENT REGULATORY POLICIES
        • 3.3.2.6     GLOBAL FINANCIAL CRISIS
        • 3.3.2.7     HIGH MARKET FRAGMENTATION AND GENERICIZATION OF BRANDED DRUGS
      • 3.3.3     BURNING ISSUES
        • 3.3.3.1     CONTAMINATION IN FORMULATION AND BULK DRUGS
        • 3.3.3.2     INFLATE DRUG PRICES
      • 3.3.4     WINNING IMPERATIVE
        • 3.3.4.1     LOW COST LABOR MARKET
      • 3.3.5     MARKET TRENDS
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     U.S.
      • 3.4.2     EUROPE
      • 3.4.3     ASIA PACIFIC
      • 3.4.4     REST OF THE WORLD
    • 3.5     PORTER’S FIVE FORCE ANALYSIS
      • 3.5.1     THREAT OF NEW ENTRANTS
      • 3.5.2     THREAT OF SUBSTITUTES
      • 3.5.3     RIVALRY AMONG EXISTING COMPETITORS
      • 3.5.4     BARGAINING POWER OF BUYERS
      • 3.5.5     BARGAINING POWER OF SUPPLIERS
    • 3.6     SUPPLY CHAIN ANALYSIS
    • 3.7     CAPACITY UTILIZATION
    • 3.8     API MANUFACTURING UNITS
    • 3.9     SELECTED TOP SELLING API
    • 3.10     MARKET SHARE ANALYSIS
  • 4     GLOBAL API MARKET OVERVIEW
    • 4.1     BY SYNTHESIS
      • 4.1.1     SYNTHETIC CHEMICALS API
      • 4.1.2     BIOTECH API
        • 4.1.2.1     INTRODUCTION
        • 4.1.2.2     MONOCLONAL ANTIBODIES
        • 4.1.2.3     RECOMBINANT PROTEINS
        • 4.1.2.4     VACCINES
        • 4.1.2.5     OTHERS
      • 4.1.3     HPAPI
    • 4.2     BY CUSTOMER BASE
      • 4.2.1     SYNTHETIC CHEMICALS
        • 4.2.1.1     BRANDED/INNOVATIVE SYNTHETIC CHEMICALS
        • 4.2.1.2     GENERIC/NON- BRANDED SYNTHETIC CHEMICALS
      • 4.2.2     BIOTECH API
        • 4.2.2.1     BIOLOGICS
        • 4.2.2.2     BIOSIMILARS
      • 4.2.3     HPAPI
    • 4.3     BY BUSINESS TYPE
      • 4.3.1     CAPTIVE
      • 4.3.2     MERCHANT
  • 5     GLOBAL API MARKET, BY THERAPEUTIC APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     ANTI-INFECTIVES
    • 5.3     ONCOLOGY
    • 5.4     CARDIOVASCULAR AND HEMATOPOIETIC SYSTEM
    • 5.5     CENTRAL NERVOUS SYSTEM
    • 5.6     RESPIRATORY SYSTEM
    • 5.7     GASTROINTESTINAL
    • 5.8     HORMONE-RELATED DISORDERS
    • 5.9     METABOLIC DISORDERS
      • 5.9.1     DIABETES
      • 5.9.2     OBESITY
    • 5.10     GENITOURINARY DISORDERS
    • 5.11     MUSCULOSKELETAL DISORDERS
    • 5.12     OTHERS
      • 5.12.1     ANESTHESIA
      • 5.12.2     EYE
      • 5.12.3     ENT (EAR NOSE THROAT) DISORDERS
  • 6     REGIONAL MARKET ANALYSIS
    • 6.1     INTRODUCTION
    • 6.2     NORTH AMERICA
    • 6.3     EUROPE
    • 6.4     ASIA PACIFIC
    • 6.5     REST OF THE WORLD
  • 7     COMPANY DEVELOPMENTS
    • 7.1     INTRODUCTION
    • 7.2     APPROVAL
    • 7.3     AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
    • 7.4     NEW PRODUCT LAUNCH
    • 7.5     MERGERS AND ACQUISITIONS
    • 7.6     OTHER DEVELOPMENTS
  • 8     MAJOR PLAYER PROFILES
    • 8.1     ALBEMARLE CORPORATION
      • 8.1.1     OVERVIEW
      • 8.1.2     FINANCIALS
      • 8.1.3     PRODUCT PORTFOLIO
      • 8.1.4     KEY DEVELOPMENTS
      • 8.1.5     BUSINESS STRATEGY
      • 8.1.6     SWOT ANALYSIS
    • 8.2     AUROBINDO PHARMA LIMITED
      • 8.2.1     OVERVIEW
      • 8.2.2     FINANCIALS
      • 8.2.3     PRODUCT PORTFOLIO
      • 8.2.4     KEY DEVELOPMENTS
      • 8.2.5     BUSINESS STRATEGY
      • 8.2.6     SWOT ANALYSIS
    • 8.3     BOEHRINGER INGELHEIM GMBH
      • 8.3.1     OVERVIEW
      • 8.3.2     FINANCIALS
      • 8.3.3     PRODUCT PORTFOLIO
      • 8.3.4     KEY DEVELOPMENTS
      • 8.3.5     BUSINESS STRATEGY
      • 8.3.6     SWOT ANALYSIS
    • 8.4     DR. REDDY’S LABORATORIES LIMITED
      • 8.4.1     OVERVIEW
      • 8.4.2     FINANCIALS
      • 8.4.3     PRODUCT PORTFOLIO
      • 8.4.4     KEY DEVELOPMENTS
      • 8.4.5     BUSINESS STRATEGY
      • 8.4.6     SWOT ANALYSIS
    • 8.5     FRESENIUS KABI
      • 8.5.1     OVERVIEW
      • 8.5.2     FINANCIALS
      • 8.5.3     PRODUCT PORTFOLIO
      • 8.5.4     KEY DEVELOPMENTS
      • 8.5.5     BUSINESS STRATEGY
      • 8.5.6     SWOT ANALYSIS
    • 8.6     LONZA GROUP LTD
      • 8.6.1     OVERVIEW
      • 8.6.2     FINANCIALS
      • 8.6.3     PRODUCT PORTFOLIO
      • 8.6.4     KEY DEVELOPMENTS
      • 8.6.5     BUSINESS STRATEGY
      • 8.6.6     SWOT ANALYSIS
    • 8.7     LUPIN LIMITED
      • 8.7.1     OVERVIEW
      • 8.7.2     FINANCIALS
      • 8.7.3     PRODUCT PORTFOLIO
      • 8.7.4     KEY DEVELOPMENTS
      • 8.7.5     BUSINESS STRATEGY
      • 8.7.6     SWOT ANALYSIS
    • 8.8     NOVARTIS INTERNATIONAL AG
      • 8.8.1     OVERVIEW
      • 8.8.2     FINANCIALS
      • 8.8.3     PRODUCT PORTFOLIO
      • 8.8.4     KEY DEVELOPMENTS
      • 8.8.5     BUSINESS STRATEGY
      • 8.8.6     SWOT ANALYSIS
    • 8.9     SUN PHARMACEUTICALS INDUSTRIES LTD
      • 8.9.1     OVERVIEW
      • 8.9.2     FINANCIALS
      • 8.9.3     PRODUCT PORTFOLIO
      • 8.9.4     KEY DEVELOPMENTS
      • 8.9.5     BUSINESS STRATEGY
      • 8.9.6     SWOT ANALYSIS
    • 8.10     TEVA ACTIVE PHARMACEUTICAL INGREDIENTS
      • 8.10.1     OVERVIEW
      • 8.10.2     FINANCIALS
      • 8.10.3     PRODUCT PORTFOLIO
      • 8.10.4     KEY DEVELOPMENTS
      • 8.10.5     BUSINESS STRATEGY
      • 8.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     ACTIVE PARMACEUTICAL INGREDIENT GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($BN)
      • TABLE 2     GLOBAL API MARKET REVENUE, BY SYNTHESIS, (2014-2022) ($BN)
      • TABLE 3     SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 4     BIOTECH API GLOBAL MARKET REVENUE, BY TYPE (2014-2022) ($BN)
      • TABLE 5     BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 6     MONOCLONAL ANTIBODIES BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 7     RECOMBINANT PROTEINS BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 8     VACCINES BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 9     OTHERS BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 10     HPAPI GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 11     SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2014-2022) ($BN)
      • TABLE 12     BRANDED/INNOVATIVE SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 13     GENERIC/NON-BRANDED SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 14     BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2014-2022) ($BN)
      • TABLE 15     BIOLOGICS BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 16     BIOSIMILARS BIOTECH API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 17     HPAPI GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 18     API GLOBAL MARKET REVENUE, BY BUSINESS TYPE (2014-2022) ($BN)
      • TABLE 19     CAPTIVE API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 20     MERCHANT API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 21     API GLOBAL MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 22     SYNTHETIC CHEMICALS GLOBAL API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS, (2014-2022) ($MN)
      • TABLE 23     BIOTECH API GLOBAL MARKET REVENUE, BY THERAPEUTIC APPLICATIONS, (2014-2022) ($MN)
      • TABLE 24     HPAPI GLOBAL MARKET REVENUE, BY THERAPEUTIC APPLICATIONS, (2014-2022) ($MN)
      • TABLE 25     ANTI-INFECTIVES API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 26     SYNTHETIC ANTI-INFECTIVES API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 27     BIOTECH ANTI-INFECTIVES API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 28     HPAPI ANTI-INFECTIVES API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 29     ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 30     SYNTHETIC ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 31     BIOTECH ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 32     HPAPI ONCOLOGYAPI GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 33     CARDIOVASCULAR AND HEMATOPOIETIC SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 34     SYNTHETIC CARDIOVASCULAR AND HEMATOPOIETIC SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 35     BIOTECH CARDIOVASCULAR AND HEMATOPOIETIC SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 36     HPAPI CARDIOVASCULAR AND HEMATOPOIETIC SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 37     CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 38     SYNTHETIC CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 39     BIOTECH CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 40     HPAPI CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 41     RESPIRATORY SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 42     SYNTHETIC RESPIRATORY SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 43     BIOTECH RESPIRATORY SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 44     HPAPI RESPIRATORY SYSTEM API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 45     GASTROINTESTINAL API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 46     SYNTHETIC GASTROINTESTINAL API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 47     BIOTECH GASTROINTESTINAL API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 48     HPAPI GASTROINTESTINAL API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 49     HORMONAL RELATED DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 50     SYNTHETIC HORMONAL RELATED API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 51     BIOTECH HORMONAL RELATED API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 52     HPAPI HORMONAL RELATED API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 53     METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 54     SYNTHETIC METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 55     BIOTECH METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 56     HPAPI METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 57     GENITO-URINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 58     SYNTHETIC GENITO-URINARY API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 59     BIOTECH GENITO-URINARY API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 60     HPAPI GENITO-URINARY API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 61     MUSCULO-SKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 62     SYNTHETIC MUSCULO-SKELETAL API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 63     BIOTECH MUSCULO-SKELETAL API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 64     HPAPI MUSCULO-SKELETAL API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 65     OTHERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 66     SYNTHETIC OTHERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 67     BIOTECH OTHERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 68     HPAPI OTHERS API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 69     API GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($BN)
      • TABLE 70     NORTH AMERICAN API MARKET REVENUE, BY SYNTHESIS, (2014-2022) ($BN)
      • TABLE 71     NORTH AMERICAN BIOTECH API MARKET REVENUE, BY TYPE (2014-2022) ($BN)
      • TABLE 72     NORTH AMERICAN SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2014-2022) ($BN)
      • TABLE 73     NORTH AMERICAN BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2014-2022) ($BN)
      • TABLE 74     NORTH AMERICAN API MARKET REVENUE, BY BUSINESS TYPE (2014-2022) ($BN)
      • TABLE 75     NORTH AMERICAN API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 76     NORTH AMERICAN SYNTHETIC CHEMICALS API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 77     NORTH AMERICAN BIOTECH API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 78     NORTH AMERICAN HPAPI MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 79     EUROPEAN API MARKET REVENUE, BY SYNTHESIS (2014-2022) ($BN)
      • TABLE 80     EUROPEAN BIOTECH API MARKET REVENUE, BY TYPE (2014-2022) ($BN)
      • TABLE 81     EUROPEAN SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2014-2022) ($BN)
      • TABLE 82     EUROPEAN BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2014-2022) ($BN)
      • TABLE 83     EUROPEAN API MARKET REVENUE, BY BUSINESS TYPE (2014-2022) ($BN)
      • TABLE 84     EUROPEAN API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 85     EUROPEAN SYNTHETIC CHEMICALS API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 86     EUROPEAN BIOTECH API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS, (2014-2022) ($BN)
      • TABLE 87     EUROPEAN HPAPI MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 88     ASIA-PACIFIC API MARKET REVENUE, BY SYNTHESIS (2014-2022) ($BN)
      • TABLE 89     ASIA-PACIFIC BIOTECH API MARKET REVENUE, BY TYPE (2014-2022) ($BN)
      • TABLE 90     ASIA-PACIFIC SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2014-2022) ($BN)
      • TABLE 91     ASIA-PACIFIC BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2014-2022) ($BN)
      • TABLE 92     ASIA-PACIFIC API MARKET REVENUE, BY BUSINESS TYPE (2014-2022) ($BN)
      • TABLE 93     ASIA-PACIFIC API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 94     ASIA-PACIFIC SYNTHETIC CHEMICALS API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 95     ASIA-PACIFIC BIOTECH API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 96     ASIA-PACIFIC HPAPI MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 97     ROW API MARKET REVENUE, BY SYNTHESIS (2015-2022) ($BN)
      • TABLE 98     ROW BIOTECH API MARKET REVENUE, BY TYPE (2014-2022) ($BN)
      • TABLE 99     ROW SYNTHETIC CHEMICALS API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2014-2022) ($BN)
      • TABLE 100     ROW BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE (2014-2022) ($BN)
      • TABLE 101     ROW API MARKET REVENUE, BY BUSINESS TYPE (2014-2022) ($BN)
      • TABLE 102     ROW API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 103     ROW SYNTHETIC CHEMICALS API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 104     ROW BIOTECH API MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 105     ROW HPAPI MARKET REVENUE, BY THERAPEUTIC APPLICATIONS (2014-2022) ($BN)
      • TABLE 106     APPROVALS (2015-2016)
      • TABLE 107     AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2015-2016)
      • TABLE 108     NEW PRODUCT LAUNCHES (2015-2016)
      • TABLE 109     MERGERS AND ACQUISITIONS (2014-2016)
      • TABLE 110     OTHER DEVELOPMENTS (2013)
      • TABLE 111     ALBEMARLE CORPORATION : TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($BN)
      • TABLE 112     ALBEMARLE CORPORATION.: TOTAL REVENUE, BY SEGMENTS (2013-2015) ($BN)
      • TABLE 113     ALBEMARLE CORPORATION.: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($BN)
      • TABLE 114     AUROBINDO PHARMA LIMITED: TOTAL REVENUE AND R&D EXPENSES (2013-15) ($BN)
      • TABLE 115     AUROBINDO PHARMA LIMITED: TOTAL REVENUE, BY SEGMENT (2013-15) ($BN)
      • TABLE 116     AUROBINDO PHARMA LIMITED: TOTAL REVENUE, BY GEOGRAPHY (2013-15) ($BN)
      • TABLE 117     BOEHRINGER INGELHEIM GMBH: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($BN)
      • TABLE 118     BOEHRINGER INGELHEIM GMBH TOTAL REVENUE, BY SEGMENTS (2013-2015) ($BN)
      • TABLE 119     BOEHRINGER INGELHEIM GMBH TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($BN)
      • TABLE 120     DR. REDDY’S LABORATORIES LIMITED: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($BN)
      • TABLE 121     DR. REDDY’S LABORATORIES LIMITED: TOTAL REVENUE, BY SEGMENT (2013-2015) ($BN)
      • TABLE 122     DR. REDDY’S LABORATORIES LIMITED: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($BN)
      • TABLE 123     FRESENIUS: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($BN)
      • TABLE 124     FRESENIUS: TOTAL REVENUE, BY BUSINESS SEGMENTS (2013-2015) ($BN)
      • TABLE 125     FRESENIUS: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($BN)
      • TABLE 126     LONZA GROUP LTD: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($BN)
      • TABLE 127     LONZA GROUP LTD: TOTAL REVENUE, BY SEGMENTS (2013-2015) ($BN)
      • TABLE 128     LONZA GROUP LTD: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($BN)
      • TABLE 129     LUPIN LIMITED: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($BN)
      • TABLE 130     LUPIN LIMITED: TOTAL REVENUE, BY SEGMENT (2013-2015) ($BN)
      • TABLE 131     LUPIN LIMITED: TOTAL REVENUE, BY API SEGMENT (2013-2015) ($BN)
      • TABLE 132     LUPIN LIMITED: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($BN)
      • TABLE 133     NOVARTIS INTERNATIONAL AG.: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($BN)
      • TABLE 134     NOVARTIS INTERNATIONAL AG.: TOTAL REVENUE, BY SEGMENTS (2013-2014) ($BN)
      • TABLE 135     NOVARTIS INTERNATIONAL AG.: TOTAL REVENUE, BY PHARMACEUTICAL SEGMENT (2013-2015) ($MN)
      • TABLE 136     NOVARTIS INTERNATIONAL AG.: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($BN)
      • TABLE 137     SUN PHARMACEUTICALS INDUSTRIES LTD: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($BN)
      • TABLE 138     SUN PHARMACEUTICALS INDUSTRIES LTD: TOTAL REVENUE, BY SEGMENTS (2013-2015) ($BN)
      • TABLE 139     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($BN)
      • TABLE 140     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY SEGMENTS (2013-2015) ($BN)
      • TABLE 141     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY GEOGRAPHY (2013-2015) ($MN)

      LIST OF FIGURES

      • FIGURE 1     GLOBAL API MARKET REVENUE, BY REGION (2015)
      • FIGURE 2     RESEARCH METHODOLOGY:ACTIVE PHARMACEUTICAL INGREDIENT MARKET
      • FIGURE 3     ACTIVE PHARMACEUTICAL INGREDIENT MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     ACTIVE PHARMACEUTICAL INGREDIENT MARKET: FORECASTING MODEL
      • FIGURE 5     API MARKET: MARKET CRACKDOWN & DATA TRIANGULATION
      • FIGURE 6     GLOBAL API MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     API MARKET: PORTER’S ANALYSIS
      • FIGURE 9     API MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     GLOBAL API CAPACITY UTILIZATION RATE, 2015
      • FIGURE 11     GLOBAL API MANUFACTURING LANDSCAPE
      • FIGURE 12     GLOBAL API MARKET SHARE ANALYSIS, 2015 (%)
      • FIGURE 13     GLOBAL API MARKET REVENUE, BY SYNTHESIS TYPE (2015 V’S 2022) ($BN)
      • FIGURE 14     GLOBAL BIOTECH API MARKET SHARE, BY SYNTHESIS TYPE (2015 V’S 2022)
      • FIGURE 15     GLOBAL SYNTHETIC CHEMICALS API MARKET SHARE, BY CUSTOMER BASE (2015 V’S 2022)
      • FIGURE 16     GLOBAL BIOTECH API MARKET SHARE, BY CUSTOMER BASE (2015 V’S 2022)
      • FIGURE 17     GLOBAL API MARKET REVENUE, BY BUSINESS TYPE (2014 – 2022)
      • FIGURE 18     GLOBAL API MARKET SHARE, BY THERAPEUTIC APPLICATIONS (2015) (%)
      • FIGURE 19     GLOBAL API MARKET SCENARIO, BY REGION (2014 - 2022) ($BN)
      • FIGURE 20     NORTH AMERICAN API MARKET REVENUE, BY SYNTHESIS, BUSINESS TYPE AND APPLICATION (2015 V’S 2022) ($BN)
      • FIGURE 21     EUROPEAN API MARKET REVENUE, BY SYNTHESIS, BUSINESS TYPE AND APPLICATION (2015 V’S 2022) ($BN)
      • FIGURE 22     ASIA PACIFIC API MARKET REVENUE, BY SYNTHESIS, BUSINESS TYPE AND APPLICATION (2015 V’S 2022) ($BN)
      • FIGURE 23     ROW API MARKET REVENUE, BY SYNTHESIS, BUSINESS TYPE AND APPLICATION (2015 V’S 2022) ($BN)
      • FIGURE 24     KEY GROWTH STRATEGIES, (2013-2016)
      • FIGURE 25     SWOT: ALBEMARLE CORPORATION
      • FIGURE 26     SWOT: AUROBINDO PHARMA LIMITED
      • FIGURE 27     SWOT: BOEHRINGER INGELHEIM GMBH
      • FIGURE 28     SWOT: DR. REDDY’S LABORATORIES LIMITED
      • FIGURE 29     SWOT: FRESENIUS KABI
      • FIGURE 30     SWOT: LONZA GROUP LTD
      • FIGURE 31     SWOT: LUPIN LIMITED
      • FIGURE 32     SWOT: NOVARTIS INTERNATIONAL AG
      • FIGURE 33     SWOT: SUN PHARMACEUTICALS INDUSTRIES LTD
      • FIGURE 34     SWOT: TEVA ACTIVE PHARMACEUTICAL INGREDIENT

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     AARTI DRUGS LTD
      • 2     ABBVIE
      • 3     ACTAVIS PHARMACEUTICALS
      • 4     AJANTHA PHARMA
      • 5     AKORN
      • 6     ALBANY MOLECULAR RESEARCH INC (AMRI)
      • 7     ALEMBIC LTD
      • 8     AMNEAL PHARMACEUTICALS LLC
      • 9     APOTEX FERMENTATION INC
      • 10     AQVIDA GMBH
      • 11     ARENA PHARMACEUTICALS
      • 12     AREVIPHARMA GMBH
      • 13     ARISTON PHARMA NOVATECH PVT LTD
      • 14     AUROBINDO PHARMA
      • 15     BASF
      • 16     BAYER PHARMA CHEMICALS
      • 17     BIOCON LTD
      • 18     BIODEL CORPORATION
      • 19     BIOSORTIA PHARMACEUTICALS
      • 20     BOEHRINGER INGELHEIM GMBH
      • 21     BRISTOL-MYERS SQUIBB
      • 22     CADILA PHARMACEUTICALS LIMITED
      • 23     CAMBREX CORPORATION
      • 24     CATALENT
      • 25     CENTURY PHARMACEUTICALS LTD
      • 26     CEPIA SANOFI
      • 27     CIPLA LIMITED
      • 28     CKD BIO
      • 29     CORDEN PHARMA
      • 30     CTX LIFESCIENCES
      • 31     DAIICHI SANKYO CHEMICAL PHARMA CO LTD
      • 32     DISHMAN PHARMACEUTICALS
      • 33     DR.REDDY’S LABORATORIES
      • 34     EIRGEN PHARMA
      • 35     EMCURE PHARMACEUTICALS LTD
      • 36     FERMION
      • 37     FLORENTIS PHARMACEUTICALS PVT LTD
      • 38     GLOBAL MERCHANTS
      • 39     HENI CHEMICAL INDUSTRIES
      • 40     INDENA
      • 41     JANSSEN PHARMACEUTICA NV
      • 42     KOSHER PHARMACEUTICALS
      • 43     KRKA PHARMACEUTICALS
      • 44     LANNETT
      • 45     LILLY PHARMACEUTICALS
      • 46     LIPTIS PHARMACEUTICALS
      • 47     LONZA GROUP
      • 48     LUPIN
      • 49     MALLINCKRODT PHARMACEUTICALS
      • 50     MEDICHEM
      • 51     MEGAFINE PHARMA LTD
      • 52     MERCK MILLIPORE
      • 53     MOLCAN
      • 54     MOREPEN
      • 55     MYLAN N.V
      • 56     NACTO PHARMA
      • 57     NANOMEDEX PHARMACEUTICALS
      • 58     NOVARTIS AG
      • 59     NOVASEP
      • 60     NOVO NORDISK
      • 61     ONCOBIOLOGICS
      • 62     ORCHID CHEMICALS & PHARMACEUTICALS LTD
      • 63     PERRIGO
      • 64     PFIZER
      • 65     PIERRE FABRE
      • 66     PRINCETON BIOMOLECULAR RESEARCH, INC
      • 67     PYTHON BIOTECH LLC
      • 68     RABLON HEALTHCARE PVT LTD
      • 69     REVA PHARMA PVT LTD
      • 70     RPG LIFE SCIENCES
      • 71     SAAMYA BIOTECH
      • 72     SANDOZ INTERNATIONAL GMBH
      • 73     SANECA PHARMACEUTICALS
      • 74     SANOFI
      • 75     SALIX PHARMACEUTICALS
      • 76     SCINOPHARM
      • 77     SHASUN
      • 78     SHREEJI PHARMA INTERNATIONAL
      • 79     SIGMA-ALDRICH
      • 80     STERLING BIOTECH LTD
      • 81     SUN PHARMACEUTICAL INDUSTRIES LTD
      • 82     SURFACHEM
      • 83     SUVEN LIFE SCIENCE LTD
      • 84     SYMBIOTEC
      • 85     TAKEDA
      • 86     TARO PHARMACEUTICALS
      • 87     TEVA PHARMACEUTICALS
      • 88     TRIFECTA PHARMACEUTICALS
      • 89     WELT CARE LIFESCIENCES PVT LTD
      • 90     WOCKHARDT
      • 91     XELLIA PHARMACEUTICALS